Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr. Scott Pollack – Ensuring Strong Hit-to-Lead Discovery Projects in the Future

In conjunction with his presentation at the London Excel at ELRIG Drug Discovery 2018, Dr. Scott Pollack, Associate Director of Biophysics and Enzymology at Sygnature Discovery, was asked:

“What is the best way to ensure strong hit-to-lead discovery projects in the future?”.

Learn more about Sygnature Discovery’s hit-to-lead capabilities here:

Hit-to-Lead

Latest News

View All

Senior appointments enhance Sygnature Discovery’s DMPK capabilities

The creation of ScanStation; drug discovery takes…

Sygnature Discovery starts 2019 with two senior…

Pathios Therapeutics and Sygnature Discovery sign strategic…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.